Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 5, 2011 Brian Orelli	Drug Approved, But No Fireworks Yet The second FDA approval for Bayer and Johnson & Johnson's Xarelto is more important.
The Motley Fool November 15, 2010 Brian Orelli	A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind.
The Motley Fool May 29, 2009 Brian Orelli	Delayed, Reason Unknown As long as Bayer and Johnson & Johnson can answer the FDA's questions relatively quickly, it shouldn't affect the companies too much.
The Motley Fool June 11, 2010 Brian Orelli	Pfizer and Bristol Coagulate Against Clots Let's see how apixaban does against warfarin before we break out the "blockbuster" stamp.
The Motley Fool November 22, 2010 Brian Orelli	Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped.
The Motley Fool June 2, 2008 Brian Orelli	The Anticoagulation Competition Bloodbath Bayer and Johnson & Johnson give Sanofi's Lovenox another beating.
The Motley Fool August 30, 2011 Brian Orelli	Pfizer and Bristol-Myers Glide Through For Pfizer and Bristol-Myers Squibb's new atrial fibrillation treatment, Eliquis, the devil seems to have left the building.
The Motley Fool November 30, 2011 Brian Orelli	Drugmakers Bleeding Out That's not what blood thinners are supposed to do.
The Motley Fool September 9, 2011 Brian Orelli	Firing Squad, It Was Not J&J and Bayer get through their advisory panel with minimal problems.
The Motley Fool June 23, 2011 Brian Orelli	In Addition, Our Drug Actually Rocks Pfizer and Bristol get good data on Eliquis.
The Motley Fool September 7, 2011 Brian Orelli	J&J and Bayer Head in Front of the Firing Squad An expanded indication for Xarelto seems unlikely.
The Motley Fool September 8, 2011 Arlene Weintraub	Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer Who will come out ahead?
The Motley Fool March 18, 2009 Brian Orelli	Johnson & Johnson and Shakespeare The stage is set for a dramatic decision.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Acute Coronary Syndrome A new class of anticoagulants is competing to dethrone difficult-to-manage warfarin, long the sole option in the prevention of stroke and other bleeding complications in the 2.5 million US patients with atrial fibrillation.
The Motley Fool November 16, 2010 Brian Orelli	Well, That Just Stinks Glaxo's Lovaza doesn't fix heart rhythm problems.
The Motley Fool March 19, 2009 Brian Orelli	One Down, One to Go Sanofi-aventis slides past an FDA panel and hopes for more good news today
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
The Motley Fool August 24, 2011 Alexander Crawford	Pfizer & Bristol-Myers to Release Highly Anticipated Data on Bloodthinner Hopeful How big could this market be?
The Motley Fool January 20, 2011 Brian Orelli	Merck's Bleeding Out Vorapaxar caused it.
The Motley Fool July 2, 2009 Robert Steyer	At Last, a Heartening Drug Approval French drug giant sanofi-aventis gets FDA approval for a drug to treat an erratic heartbeat.
The Motley Fool November 7, 2011 David Williamson	Health-Care News You Can't Afford to Miss Highlighting the day's health-care stories: FDA approval for Johnson & Johnson... Inhibitex kept its streak of double-digit gains alive with another 14% surge today... 13% plunge for Optimer Pharmaceuticals...
The Motley Fool August 24, 2007 Brian Orelli	Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool January 14, 2011 Brian Orelli	Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool October 13, 2009 Brian Orelli	J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source.
The Motley Fool February 3, 2011 Brian Orelli	Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window.
The Motley Fool July 10, 2007 Brian Orelli	Sometimes, the Same Is Good Enough Bristol-Myers Squibb's new drug doesn't work better, but it's easier to take. Investors, take note.
The Motley Fool September 30, 2011 David Williamson	This Week in Health Care Pharma news about Pfizer, AstraZeneca, and the multibillion-dollar battle to replace the maligned blood-thinner warfarin.
The Motley Fool May 18, 2009 Brian Orelli	Onyx Cries, "Et Tu, Brute?" The company is suing for the rights to a drug that marketing partner Bayer is developing.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool September 5, 2006 Brian Gorman	Bayer Rising? Bayer still has some hoops to jump through before it's in tip-top shape, but the company has some tantalizing opportunities. Investors, it's not too early to put the German conglomerate on the watch list.
American Family Physician July 15, 2002 Dana E. King	Acute Management of Atrial Fibrillation: Part II. Prevention of Thromboembolic Complications Family physicians should be familiar with the acute management of atrial fibrillation and the initiation of chronic therapy for this common arrhythmia. Part II of this two-part article focuses on the prevention of thromboembolic complications using anticoagulation.
Chemistry World May 29, 2014 Phillip Broadwith	Boehringer to settle blood thinner drug suits for $650m Boehringer-Ingelheim has committed $650 million to settle around 4000 US court cases relating to its anticoagulant stroke prevention drug Pradaxa (dabigatran).
The Motley Fool March 5, 2008 Brian Orelli	Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned.
American Family Physician June 15, 2005 Mark H. Ebell	Decision-Making Tool for Treating Patients with Nonvalvular Atrial Fibrillation What is the risk of stroke in a patient with nonvalvular atrial fibrillation, and should that patient be given warfarin (Coumadin) or aspirin?
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool November 26, 2010 Brian Orelli	Get It Together, Johnson & Johnson Another day, another recall.
The Motley Fool September 29, 2011 Brian Orelli	Investors Guide to the New PDUFA Changes are in the air for drugmakers and the FDA.
The Motley Fool February 28, 2011 Brian Orelli	Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo.
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
The Motley Fool July 9, 2010 Brian Orelli	Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.